Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Maxvax Completes $74 Million Series B for China Vaccine Development

publication date: Jul 28, 2022

Chengdu’s Maxvax raised $74 million in a Series B round to support clinical trials of several pipeline vaccine candidates, including herpes zoster and rotavirus for neonates and children under 5 years. The company is currently developing more than ten new vaccines, with two candidates in clinical trials. It expects IND approvals for several more in the next year and will start R&D for animal vaccines as well. The B round was led by China Life Private Equity Investment, with Sherpa Investment, Hillhouse Venture Capital, Fangshizhen Capital and Xinshang Capital participating. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here


BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here


Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here